{
  "buildId": "5lGULuFSFhUrfWgBpMJq_",
  "gssp": true,
  "isFallback": false,
  "page": "/calc/[...slug]",
  "props": {
    "__N_SSP": true,
    "pageProps": {
      "calc": {
        "before_use": "",
        "calc_type": "calculator",
        "chief_complaint_en": [
          "Extremity Pain",
          "Neck Pain",
          "Pain",
          "Weakness"
        ],
        "cmeEndDate": "2025-07-25 00:00:00+00+17",
        "cmeLastReviewed": "2022-07-25 00:00:00+00+17",
        "cmeReleaseDate": "2020-10-08 00:00:00+00+00",
        "cmeVersion": "3929.1",
        "cme_status": "enabled",
        "content": {
          "about": {
            "evidence_based_medicine_en": "<p>The Mayo Clinic analyzed 3,549 patients with myeloma referred between 1970 and 1995. 276 (8%) fulfilled criteria for smoldering multiple myeloma (SMM).</p> <p>Patients’ bone marrows, labs and longitudinal records were reviewed. The end point was progression to active myeloma or amyloidosis requiring therapy.</p> <p><strong>Pertinent outcomes:</strong></p> <ol> <li>85% of SMM patients died, median follow up 11.6 years.</li> <li>57% developed active MM, with median survival after of 3.4 years.</li> <li>Cumulative probability of progression 51% at 5 years, 66% at 10 years, and 73% at 15 years.</li> <li>Risk of progression was 10% per year for the first 5 years, 3% per year for next 5 years, then 1% per year for the next 10 years.</li> </ol>",
            "formula_en": "<p><strong>High risk</strong></p>\n<ul>\n<li>BM plasmacytosis &ge;10% AND</li>\n<li>Serum monoclonal protein &ge;3 g/dL</li>\n</ul>\n<p><strong>Intermediate risk</strong></p>\n<ul>\n<li>BM plasmacytosis &ge;10% AND</li>\n<li>Serum monoclonal protein &lt;3 g/dL</li>\n</ul>\n<p><strong>Low risk</strong></p>\n<ul>\n<li>BM plasmacytosis &lt;10% AND</li>\n<li>Serum monoclonal protein &ge;3 g/dL</li>\n</ul>",
            "more_info_en": "<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td rowspan=\"2\">&nbsp;</td>\n<td colspan=\"3\">\n<p><strong>Risk of progression</strong></p>\n</td>\n<td rowspan=\"2\">\n<p><strong>Median time to progression</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>At 5 years</strong></p>\n</td>\n<td>\n<p><strong>At 10 years</strong></p>\n</td>\n<td>\n<p><strong>At 15 years</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>High risk</strong></p>\n</td>\n<td>\n<p>69%</p>\n</td>\n<td>\n<p>77%</p>\n</td>\n<td>\n<p>87%</p>\n</td>\n<td>\n<p>27 months (~2 years)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Intermediate risk</strong></p>\n</td>\n<td>\n<p>43%</p>\n</td>\n<td>\n<p>64%</p>\n</td>\n<td>\n<p>70%</p>\n</td>\n<td>\n<p>93 months (~8 years)</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Low risk</strong></p>\n</td>\n<td>\n<p>15%</p>\n</td>\n<td>\n<p>33%</p>\n</td>\n<td>\n<p>39%</p>\n</td>\n<td>\n<p>228 months (~19 years)</p>\n</td>\n</tr>\n</tbody>\n</table>",
            "references_list": {
              "Clinical Practice Guidelines": [
                {
                  "href": "",
                  "text": ""
                }
              ],
              "Manufacturer Website": [
                {
                  "href": "",
                  "text": ""
                }
              ],
              "Original/Primary Reference": [
                {
                  "href": "http://www.ncbi.nlm.nih.gov/pubmed/17582068",
                  "text": "Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 Jun 21;356(25):2582-90. PMID:17582068."
                }
              ],
              "Other References": [
                {
                  "href": "",
                  "text": ""
                }
              ],
              "Outcomes": [
                {
                  "href": "",
                  "text": ""
                }
              ],
              "Validation": [
                {
                  "href": "http://www.bloodjournal.org/content/126/23/4251",
                  "text": "Kastritis E, Terpos E, et al. Validation of the Novel Criteria for the Definition of Symptomatic Myeloma: A Single Center Experience in 216 Patients with the Previous Diagnosis of Asymptomatic Disease. Blood 2015 126:4251"
                }
              ],
              "Validations": []
            }
          },
          "contributor": {
            "expert_name": [
              "Randall Pierce, MD"
            ]
          },
          "creator": [
            {
              "approved": null,
              "name": "Dr. Robert A. Kyle",
              "qa_en": null
            }
          ],
          "how_to_use": {
            "pearls_pitfalls_en": "<p>The Asymptomatic Myeloma Prognosis calculator classifies smoldering multiple myeloma (MM) patients into 3 prognostic groups, with differing risks of progression to active MM or amyloidosis.</p> <p>The criteria developed by the International Myeloma Working Group for diagnosis of smoldering multiple myeloma (SMM, or asymptomatic MM) are:</p> <ol> <li>Serum monoclonal protein ≥3 g/dL OR</li> <li>Plasma cells in bone marrow (BM) ≥ 10% AND</li> <li>No evidence of end-organ damage (no anemia, bone lesions, renal dysfunction, hypercalcemia, or recurrent bacterial infections)</li> </ol> <p>Prognosis and risk for progression to MM are quite variable.</p> <p>Overall progression risk was 10%/year for the first five years, 3%/yr for the next five years, then 1%/year for the next ten years. Cumulative risk for progression was 73% at 15 years.</p>",
            "use_case_en": "<p>Newly diagnosed multiple myeloma (MM) patients meeting International Myeloma Working Group criteria for smoldering or asymptomatic MM (see <a href=\"#pearls-pitfalls\">Pearls/Pitfalls</a> for criteria).</p>",
            "why_use_en": "<ul> <li>Provides prognostic information for patients.</li> <li>Suggests patients who may need closer follow up.</li> <li>Allows for stratification of patients on clinical trials potentially evaluating newer, targeted myeloma therapies.</li> <li>Does not require FISH studies, cytogenetic, or MRI bone studies, which may add further discrimination but are not widely available; hence, generalizability is preserved in settings with limited availability of these studies.</li> </ul>"
          },
          "next_steps": {
            "advice_en": "<p>Patients with smoldering or asymptomatic MM are currently observed. However, clinical trials should be sought for appropriate patients given the rapid progress in development of novel active agents.</p>",
            "critical_actions_en": "",
            "management_en": ""
          },
          "related_resources": {
            "guidelines": [],
            "interests": [],
            "mdcalc_rating": {
              "clinical": "",
              "evidence": "",
              "popularity": ""
            },
            "partner_contact": [],
            "sdm_tool": [],
            "teaching": [],
            "videos": []
          },
          "reviewer": []
        },
        "disease_en": [
          "Cancer",
          "Hematologic Malignancy",
          "Multiple Myeloma"
        ],
        "dosing": false,
        "equation_logic": "4725fc0e76e94c85bf00a601a488d5c7",
        "equation_logic_text": "// Asymptomatic Myeloma Prognosis\nvar calc_output = [];\n\nvar bmp; \t\t\t\t// bone marrow plasmacytosis \nvar smp; \t\t\t\t// serum monoclonal protein\nvar risk_group = '';\t// risk group\nvar risk_percent = '';\t// risk in percentage\nvar time = '';\t\t\t// time to progression in years\nvar msg = ''; \t\t\t// message\n\nif (bmp == 0 && smp == 0) {\n\trisk_group = 'High';\n\trisk_percent = '69%'; \n\tmsg = 'Risk of progression at 5 years<br/><br/><strong>77%</strong> at 10 years<br/><strong>87%</strong> at 15 years';\n\ttime = '27';\n}\nif (bmp == 0 && smp == 1) {\n\trisk_group = 'Intermediate';\n\trisk_percent = '43%'; \n\tmsg = 'Risk of progression at 5 years<br/><br/><strong>64%</strong> at 10 years<br/><strong>70%</strong> at 15 years';\n\ttime = '93';\n}\n\nif (bmp == 1 && smp == 0) {\n\trisk_group = 'Low';\n\trisk_percent = '15%';\n\tmsg = 'Risk of progression at 5 years<br/><br/><strong>33%</strong> at 10 years<br/><strong>39%</strong> at 15 years'; \n\ttime = '228';\n}\nif (bmp == 1 && smp == 1) {\n\trisk_group = '';\n\trisk_percent = ''; \n\tmsg = 'Patient does not meet criteria for asymptomatic myeloma (see Pearls/Pitfalls for criteria)';\n\ttime = '';\n}\nif (bmp + smp < 2) {\ncalc_output.push({ // message on app\n    name: 'mini',\n    value: risk_group,\n    value_text: 'risk',\n    message: \"\"\n});\n}\nif (bmp == 1 && smp == 1) {\ncalc_output.push({ // message on app\n    name: 'mini',\n    value: '',\n    value_text: '',\n    message: msg\n});\n}\nif (bmp + smp < 2) {\ncalc_output.push({\n    name: 'risk_group',\n    value: risk_group,\n    value_text: ' risk',\n    message: \"\"\n});\n}\ncalc_output.push({\n    name: 'risk',\n    value: risk_percent,\n    value_text: '',\n    message: msg\n});\nif (bmp + smp < 2) {\ncalc_output.push({\n    name: 'time',\n    value: time,\n    value_text: ' months',\n    message: 'Median time to progression'\n});\n}",
        "favorite_id": 3929,
        "full_title_en": "Asymptomatic Myeloma Prognosis",
        "input_schema": [
          {
            "conditionality": "",
            "default": null,
            "label_en": "Bone marrow plasmacytosis",
            "name": "bmp",
            "optional": false,
            "options": [
              {
                "label": "≥10%",
                "value": 0
              },
              {
                "label": "<10%",
                "value": 1
              }
            ],
            "show_points": false,
            "tips_en": "Average % from bone marrow aspirate and core biopsy",
            "type": "toggle"
          },
          {
            "conditionality": "",
            "default": null,
            "label_en": "Serum monoclonal protein, g/dL",
            "name": "smp",
            "optional": false,
            "options": [
              {
                "label": "≥3",
                "value": 0
              },
              {
                "label": "<3",
                "value": 1
              }
            ],
            "show_points": false,
            "tips_en": "On serum protein electrophoresis",
            "type": "toggle"
          }
        ],
        "instructions_en": "",
        "logic_language": "javascript",
        "md5": "6fb421ce64bdbf9dc743dafc165042cf",
        "medium_description_en": "<p>Predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.</p>",
        "purpose_en": [
          "Prognosis"
        ],
        "search_abbreviation_en": [
          "mm",
          "multiple myeloma",
          "myeloma",
          "smoldering myeloma",
          "asymptomatic myeloma",
          "prognosis"
        ],
        "search_id": "c-3929",
        "seo": {
          "keywords_en": "smm, smoldering myeloma",
          "meta_description_en": "The Asymptomatic Myeloma Prognosis predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis."
        },
        "short_description_en": "Predicts risk of progression to active myeloma or amyloidosis.",
        "short_title_en": "Asymptomatic Myeloma Prognosis",
        "slug": "asymptomatic-myeloma-prognosis",
        "specialty_en": [
          "Hematology and Oncology"
        ],
        "system_en": [
          "Hematologic",
          "Oncologic"
        ]
      },
      "contributors": [
        {
          "contributors_page": false,
          "description": "<p>Randall (Randy) Pierce is in private practice with Northwest Georgia Oncology Centers in Carrollton, Georgia, where he has been in practice since 1998. After graduating from the University of Georgia in 1988, he attended medical school at the Medical College of Georgia. His internal medicine residency and hematology/oncology training were completed at Wake Forest University/Baptist Medical Center in 1998. Dr. Pierce treats most malignancies and has a special interest in myeloma and lymphoma. He is married, has 3 children, and enjoys playing tennis and deep sea fishing.</p>",
          "firstName": "Randall",
          "hasDisclosure": [],
          "img": "randall-pierce.jpg",
          "lastName": "Pierce",
          "name": "Randall Pierce, MD",
          "signedCOI": true,
          "status": "Past",
          "target": "randall-pierce"
        }
      ],
      "creators": [
        {
          "about_en": "<p>Robert A. Kyle, MD, is a professor of medicine and laboratory medicine and pathology at the Mayo Clinic in Rochester, Minnesota. He is widely regarded as a pioneer in multiple myeloma research, having published numerous critical papers on topics including monoclonal gammopathies, multiple myeloma, amyloidosis, and macroglobulinemia.</p>",
          "deceased": false,
          "description": "",
          "firstName": "",
          "img": "",
          "lastName": "",
          "name": "Dr. Robert A. Kyle",
          "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-robert-a-kyle.jpg",
          "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=kyle+ra%5Bau%5D",
          "signedCOI": false
        }
      ],
      "envs": {
        "CANONICAL_URL_ROOT": "https://www.mdcalc.com",
        "CONTENT_SERVER_TAG": "WEB_PROD",
        "RECAPTCHA_PUBLIC_KEY": "6Lcu1mMkAAAAAAwmSDO3I7JNaUo9YtZ3jnrzTP6a",
        "STRIPE_PUB_KEY": "pk_live_yYm2UzDzaudhFgqWcKbv9vH7"
      },
      "faqs": [
        {
          "cme_faq": {
            "answer": "<p>MDCalc&rsquo;s Continuing Medical Education (CME) service allows users to easily earn AMA PRA Category 1 CreditsTM through regular use of MDCalc. Simply put, on top of getting the best medical calculators in the world, your usage will help you achieve your annual CME requirements, including specialty CME, without any extra effort.</p>",
            "question": "What is MDCalc CME?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Yes, in support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MDCalc Ltd. Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.</p>",
            "question": "Is MDCalc CME accredited?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Only United States attending physicians, nurse practitioners, nurses, and physician assistants are eligible for our CME service.</p>",
            "question": "Who can enroll and how?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>We have over 275 CME-eligible calculators across various specialties. You can read the clinical content supporting any CME calculators to start earning. Once you have viewed all the supporting content for a calculator, you will have officially earned the credit amount (0.5 credits) and will be able to redeem a certificate. For now, only calc content in CME-eligible calcs is eligible for CME credits, however, we&rsquo;ll be expanding our CME service to include more of our content in the future.</p>",
            "question": "What activities can I do to earn CME credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Simply use our search bar or visit our homepage to easily find CME-eligible calcs. You must be enrolled in our CME service to see which calcs are CME-eligible.</p>",
            "question": "Where can I find calcs with which I can earn credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Once you&rsquo;ve enrolled in our CME service, you will have a personal CME Dashboard where you can view all of your earned credits. You can navigate to the dashboard by clicking the CME button in the header at the top of any page.</p>",
            "question": "Where can I see which credits I’ve earned?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Go to your CME Dashboard and select the credits you&rsquo;d like to redeem, fill out a few dropdown answers about how you used the calc, and then proceed to checkout.</p>",
            "question": "How do I redeem CME credits?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>No. Earning credits as you use calcs is free, but either you (or your employer) will need to purchase an annual subscription to redeem your CME certificates.</p>",
            "question": "Are CME credits free?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Just like with earned credits, you can view your CME certificates on your CME Dashboard in the &ldquo;CME Certificates&rdquo; tab. Certificates include a list of all of the calcs for which CME was earned along with a tally of the specialty CME.</p>",
            "question": "Where can I see my CME certificates?",
            "type": "Using"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>One year from the date of purchase.</p>",
            "question": "How long do credits in an annual subscription last?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>General; Addiction and Controlled Substances; Cardiac Care; Domestic and Intimate Partner Violence; Geriatrics; HIV and Infectious Disease; Hospice, End-of-Life, Terminal Illness, and Palliative Care; Mental and Behavioral Health; Pain Management; Pediatrics; Stroke; and Trauma.</p>",
            "question": "What specialty CME credits are included in the plan?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Your gift card will be sent via email within 1-2 business days of making your purchase. You will be able to select from the following options - Visa, Amazon.com, Apple. Be sure to claim your gift card offer within 90 days of receiving the email.</p>\n<p>Your CME purchase may have implications for tax reporting purposes. The cost of your CME product may or may not be tax-deductible when used for professional purposes. Any reimbursed amount for incentives must be declared as personal income for tax purposes. Please consult your tax advisor. MDCalc does not provide tax advice.</p>",
            "question": "I ordered a CME package with a gift card. How does it work?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Per the new guidelines from ACCME, the receipt will separate the cost you paid into the cost of the gift card and the cost of the CME learning activity.</p>",
            "question": "What will show on my receipt for CME when it includes a gift card?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>You can get a refund (minus any promotional gift amount) within 30-days if the ease of earning and redeeming does not meet your expectations and if you have redeemed no more than 4 credits. Please email <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> to request a refund.</p>",
            "question": "How do I get a refund if I'm not satisfied?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>You can upgrade your subscription throughout your billing cycle and pay the difference for a higher plan. You may request to downgrade your plan to a lower level to coincide with your next renewal. Please email <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> to request changes.</p>",
            "question": "How do I later upgrade to a different plan if I need more credits?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>Gift card plans are available for 1 year and do not auto-renew. Standard, non gift-card subscriptions are auto-renewed annually. You can disable the automatic renewal of your subscription at any time by emailing <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a>.</p>",
            "question": "Do CME plans auto-renew?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>If you&rsquo;re part of a team or practice that wants to sign up five or more physicians, please email us at <a href=\"mailto:team@mdcalc.com\" target=\"_blank\" rel=\"noopener\">team@mdcalc.com</a> for more information.</p>",
            "question": "How do I get information on a discounted bulk subscription program for my institution, team, or practice?",
            "type": "Purchasing"
          }
        },
        {
          "cme_faq": {
            "answer": "<p>On July 28, 2022, ACCME updated the guidelines regarding the use of high-value incentives. These guidelines allow for the use of gift card rewards in a regulated manner. Visit the ACCME website to read their guidelines.</p>",
            "question": "Did the ACCME decide to regulate gift cards?",
            "type": "Purchasing"
          }
        }
      ],
      "headConfig": {
        "canonicalUrl": "/calc/3929/asymptomatic-myeloma-prognosis",
        "description": "The Asymptomatic Myeloma Prognosis predicts risk of progression of asymptomatic (smoldering) multiple myeloma to active myeloma or amyloidosis.",
        "keywords": "smm, smoldering myeloma",
        "title": "Asymptomatic Myeloma Prognosis"
      },
      "isCMECalc": true,
      "measurements": [],
      "relCalcs": [
        {
          "calcId": 3842,
          "short_title_en": "Revised Myeloma ISS",
          "slug": "revised-multiple-myeloma-international-staging-system-r-iss"
        },
        {
          "calcId": 10233,
          "short_title_en": "Multiple Myeloma Diagnostic Criteria",
          "slug": "multiple-myeloma-diagnostic-criteria"
        },
        {
          "calcId": 10232,
          "short_title_en": "Multiple Myeloma Response Criteria",
          "slug": "multiple-myeloma-response-criteria"
        }
      ],
      "societies": {
        "American Association for the Study of Liver Diseases": {
          "abbreviation": "AASLD",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.aasld.org/"
        },
        "American College Of Emergency Physicians": {
          "abbreviation": "ACEP",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/apps.mdcalc.com/images/american-college-of-emergency-physicians-squarelogo.png",
          "web_link": "https://www.acep.org/"
        },
        "American College of Gastroenterology": {
          "abbreviation": "ACG",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/acg_logo.png",
          "web_link": "https://gi.org/"
        },
        "American College of Rheumatology": {
          "abbreviation": "ACR",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.rheumatology.org/"
        },
        "American Gastroenterological Association": {
          "abbreviation": "AGA",
          "description": "plain-text",
          "img": "https://apps.mdcalc.com/images/societies/aga.jpeg",
          "web_link": "https://gastro.org"
        },
        "American Heart Association": {
          "abbreviation": "AHA",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/apps.mdcalc.com/images/societies/+AHA+(American+Heart+Association).png",
          "target": "aha",
          "web_link": "http://www.heart.org/HEARTORG/"
        },
        "American Urological Association": {
          "abbreviation": "AUA",
          "description": "plain-text",
          "img": "https://s3-us-west-2.amazonaws.com/cdn-web-img.mdcalc.com/logo/other_society.png",
          "web_link": "https://www.auanet.org/"
        },
        "EB Medicine": {
          "abbreviation": "EB Medicine",
          "description": "EB Medicine is the premier provider of evidence-based clinical content and CME resources for emergency medicine practitioners.",
          "img": "https://cdn-web-img.mdcalc.com/other/eb_medicine-icon-only.jpg",
          "target": "eb-medicine",
          "web_link": "http://www.ebmedicine.net/"
        },
        "MDCalc CME": {
          "abbreviation": "MDCalc CME",
          "img": "https://cdn-web-img.mdcalc.com/Stroke-CME-content.jpg",
          "web_link": "https://www.mdcalc.com/stroke-cme?utm_source=NIHSS_calc&utm_medium=NIHSS_calc&utm_campaign=NIHSS_calc"
        },
        "OTHER": {
          "abbreviation": "OTHER"
        },
        "Postgraduate Institute for Medicine": {
          "abbreviation": "PIM",
          "description": "plain-text",
          "img": "https://cdn-web-img.mdcalc.com/PIM-circle-COLOR.jpeg",
          "target": "pim",
          "web_link": "https://www.pimed.com/"
        },
        "VACO Podcast": {
          "description": "Listen to the VACO co-creators break down how to use VACO\\, what it does\\, and what it doesn’t.",
          "img": "https://cdn-web-img.mdcalc.com/content/podcast 2.png",
          "web_link": "https://www.stimuluspodcast.com/post/32-the-covid-mortality-score-vaco"
        }
      },
      "validSections": [
        "whenToUseViewed",
        "pearlsPitfallsViewed",
        "whyUseViewed",
        "nextStepsViewed",
        "evidenceViewed"
      ]
    }
  },
  "query": {
    "slug": [
      "3929",
      "asymptomatic-myeloma-prognosis"
    ]
  },
  "scriptLoader": []
}